CONTROLLED THERAPEUTICS (SCOTLAND) LTD

1 Redwood Place, Peel Park Campus, East Kilbride, G74 5PB

Controlled Therapeutics wins prestigious Queen's Award for Enterprise

Date 21st April 2010

Controlled Therapeutics (Scotland) Ltd (CTS) is delighted to announce it has won a Queen's Award for Enterprise in the International Trade category. The honour recognises the company's export earnings from its leading product, called Propess® throughout the EU and Cervidil® in the USA. Propess/Cervidil is a vaginal insert containing the prostaglandin dinoprostone, which is used to induce labour in women who are at or near term in their pregnancy. The product's unique controlled drug release mechanism effectively ripens the cervix and minimises the potential for adverse events during labour. This has enabled Propess/Cervidil to become the leading brand for induction of labour in the USA and EU. To date, over 5 million babies have been successfully delivered with the product.

Since 1993, CTS has been a wholly owned subsidiary of Cytokine PharmaSciences, Inc. of the USA. It is located at East Kilbride, near Glasgow, and currently employs 69 staff. CTS specialises in the development and manufacture of products based on the company's unique proprietary controlled release drug delivery technologies.

CTS' Managing Director, Dr Cameron Macdonald, commented "Receiving such recognition is a tremendous achievement for the company and our staff. We operate in a highly competitive market dominated by some of the largest global corporations. Our success has been built on a strategy of focusing on the development of specialist products which address unmet clinical needs within the women's health market. Propess/Cervidil is now exported to 29 countries, with registrations being sought in a number of others. We have achieved this global reach by partnering with companies which have a proven track record of success in their markets."

Denny Willson, President & CEO of Cytokine PharmaSciences, stated: "This is the second time CTS has won the Queen's Award for Enterprise. This is a tremendous source of pride for all of us and reflects well not just on CTS' ability to innovate – for which it won its first award in 2003 – but also to convert that innovation into successful therapeutics."

Telephone: 01355 239166 Facsimile: 01355 263661

Website: www.ctscotland.com E-mail: info@ctscotland.com

Reg. Office: 151 St Vincent Street, Glasgow G2 5NJ.
Reg. No. 100269 VAT Reg. No.447 9067 15

CELEBRATING OVER 20 YEARS
SERVING PATIENTS SINCE 1986

CTS has three other products in development based on the same controlled release vaginal insert used for Propess/Cervidil. The Misodel® vaginal insert, a next generation product for induction of labour but based on the prostaglandin misoprostol, is in Phase III. Premis™, which is currently in Phase II, also contains misoprostol, but at higher doses for achieving cervical softening in non-pregnant women about to undergo hysteroscopic procedures. The third product, C-Vad™, contains the antibacterial clindamycin and is being developed for the treatment of bacterial vaginosis.

CTS has also developed a new polymer technology which will enable drug delivery in the form of vaginal rings for periods from one week to several months. A first candidate ring product is now in pre-clinical development with clinical trials scheduled to begin in 2011. The Company is also collaborating with the American not-for-profit research organization, CONRAD, on the development of a vaginal ring containing microbicides to help prevent the transmission of HIV in susceptible populations.

ENDS

For further information contact

Dr Cameron Macdonald

Managing Director

Controlled Therapeutics (Scotland) Ltd

01355 239166